The post Here’s How Much Medline’s Founding Family Is Worth, Per Pending IPO appeared on BitcoinEthereumNews.com. Medline’s founding family (from left to right): Jim Abrams, Charlie Mills and Andy Mills. Jeff Sciortino for Forbes The Mills family cashed out a majority stake in the family’s medical supplies firm to private equity in 2021. But the coming $50 billion IPO shows that even what they continue to hold is worth a fortune. Combined, Forbes estimates they’re worth $20 billion. Medical-supplies giant Medline’s IPO is set to be this winter’s blockbuster–worth up to $55 billion. Documents for it also reveal for the first time the remaining stake of the Mills family, who founded the company in 1910 and ran it for generations. In 2021, the family sold a majority stake in the private company to private equity for $30 billion. A new securities filing shows that the Mills family’s stake is worth $6 billion to $7 billion, by Forbes estimates based on the disclosed shareholdings of Mozart HoldCo and an expected share price of $26-to-$30 per share. Combined with an estimated pretax stake of $22 billion from the earlier stake sale, that would give the Mills family–including Charlie Mills, the company’s former CEO; Andy Mills, his cousin and former president; and Jim Abrams, Andy’s brother-in-law and the former chief operating officer–a combined net worth of $20 billion by Forbes estimates. That makes them worth 18 times the $1.1 billion that Forbes calculated they were worth in 2014. The family set up a family office called Council Ring Capital following the 2021 sale, and the trio began stepping back from operations in 2023. Medline did not immediately respond to an email seeking comment. Medline’s roots go back to 1910 when A.L. Mills–the great-grandfather of Charlie Mills–moved from small town Arkansas to Illinois. He sold handmade butcher’s aprons to workers in the city’s vast meatpacking district. After a nun who… The post Here’s How Much Medline’s Founding Family Is Worth, Per Pending IPO appeared on BitcoinEthereumNews.com. Medline’s founding family (from left to right): Jim Abrams, Charlie Mills and Andy Mills. Jeff Sciortino for Forbes The Mills family cashed out a majority stake in the family’s medical supplies firm to private equity in 2021. But the coming $50 billion IPO shows that even what they continue to hold is worth a fortune. Combined, Forbes estimates they’re worth $20 billion. Medical-supplies giant Medline’s IPO is set to be this winter’s blockbuster–worth up to $55 billion. Documents for it also reveal for the first time the remaining stake of the Mills family, who founded the company in 1910 and ran it for generations. In 2021, the family sold a majority stake in the private company to private equity for $30 billion. A new securities filing shows that the Mills family’s stake is worth $6 billion to $7 billion, by Forbes estimates based on the disclosed shareholdings of Mozart HoldCo and an expected share price of $26-to-$30 per share. Combined with an estimated pretax stake of $22 billion from the earlier stake sale, that would give the Mills family–including Charlie Mills, the company’s former CEO; Andy Mills, his cousin and former president; and Jim Abrams, Andy’s brother-in-law and the former chief operating officer–a combined net worth of $20 billion by Forbes estimates. That makes them worth 18 times the $1.1 billion that Forbes calculated they were worth in 2014. The family set up a family office called Council Ring Capital following the 2021 sale, and the trio began stepping back from operations in 2023. Medline did not immediately respond to an email seeking comment. Medline’s roots go back to 1910 when A.L. Mills–the great-grandfather of Charlie Mills–moved from small town Arkansas to Illinois. He sold handmade butcher’s aprons to workers in the city’s vast meatpacking district. After a nun who…

Here’s How Much Medline’s Founding Family Is Worth, Per Pending IPO

Medline’s founding family (from left to right): Jim Abrams, Charlie Mills and Andy Mills.

Jeff Sciortino for Forbes

The Mills family cashed out a majority stake in the family’s medical supplies firm to private equity in 2021. But the coming $50 billion IPO shows that even what they continue to hold is worth a fortune. Combined, Forbes estimates they’re worth $20 billion.

Medical-supplies giant Medline’s IPO is set to be this winter’s blockbuster–worth up to $55 billion. Documents for it also reveal for the first time the remaining stake of the Mills family, who founded the company in 1910 and ran it for generations. In 2021, the family sold a majority stake in the private company to private equity for $30 billion.

A new securities filing shows that the Mills family’s stake is worth $6 billion to $7 billion, by Forbes estimates based on the disclosed shareholdings of Mozart HoldCo and an expected share price of $26-to-$30 per share.

Combined with an estimated pretax stake of $22 billion from the earlier stake sale, that would give the Mills family–including Charlie Mills, the company’s former CEO; Andy Mills, his cousin and former president; and Jim Abrams, Andy’s brother-in-law and the former chief operating officer–a combined net worth of $20 billion by Forbes estimates. That makes them worth 18 times the $1.1 billion that Forbes calculated they were worth in 2014. The family set up a family office called Council Ring Capital following the 2021 sale, and the trio began stepping back from operations in 2023.

Medline did not immediately respond to an email seeking comment.

Medline’s roots go back to 1910 when A.L. Mills–the great-grandfather of Charlie Mills–moved from small town Arkansas to Illinois. He sold handmade butcher’s aprons to workers in the city’s vast meatpacking district. After a nun who worked as a seamstress at a local hospital asked Mills if he could make and sell them hospital garments, the medical business was born. Over the subsequent decades, the company invented the first surgeon’s gown with 360-degree coverage, were among the first to commercialize the blue and green fabrics worn in the operating room to cut down on the lights’ glare, and were first to introduce the now ubiquitous pink-and-blue striped blankets for newborns.

Though Medline’s supplies–everything from baby blankets to bandages–are everywhere, the Mills family was largely unknown until Forbes profiled them in 2020 when Covid-19 was at its peak. At the time, its distribution of medical supplies to nursing homes, pharmacies and 45% of hospital systems nationwide was a critical part of the country’s pandemic response.

Then, in June 2021, the family–which had till then owned 100% of the company–sold a majority stake to a consortium of private-equity firms that included Blackstone Group, Carlyle Group and Hellman & Friedman, who beat out other blue-chip bidders. In October 2023, current CEO Jim Boyle took on that role, the first non-family member to hold it.

Private-equity ownership has been good for Medline. The company’s sales reached $25.5 billion in 2024, up 83% from $13.9 billion five years earlier. Meanwhile profits rebounded to $1.2 billion last year, compared with a small loss two years earlier.

MORE FROM FORBES

ForbesThis Robotic Surgery Legend Is Pouring $100 Million Into Next-Gen Medical StartupsForbesThis Haiti-Born Doctor Built A $6 Billion Business Developing Drugs For Depression And Alzheimer’sForbesHow A Tiny Polish Startup Became The Multi-Billion-Dollar Voice Of AIForbesHow Donald Trump Jr’s Fortune Jumped Six-Fold In A YearForbesCompanies Cut Prices For Blockbuster Weight-Loss Drugs

Source: https://www.forbes.com/sites/amyfeldman/2025/12/08/medlines-mills-founding-family-has-6-billion-plus-stake-in-its-upcoming-blockbuster-ipo/

Market Opportunity
Andy Logo
Andy Price(ANDY)
$0.0000808
$0.0000808$0.0000808
-3.34%
USD
Andy (ANDY) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Kalshi Jumps to 62% Market Share While Polymarket Eyes $10B Valuation

Kalshi Jumps to 62% Market Share While Polymarket Eyes $10B Valuation

The post Kalshi Jumps to 62% Market Share While Polymarket Eyes $10B Valuation appeared on BitcoinEthereumNews.com. Fintech 19 September 2025 | 16:03 Event-based trading platforms are no longer niche experiments – they’re emerging as a major arena where finance, crypto, and information converge. After months of subdued activity, volumes are climbing again, and U.S.-regulated Kalshi has unexpectedly taken the lead. Betting on Everything From Rates to Sports Analysts at Bernstein describe prediction markets as a new “interface for information,” where users speculate not only on sports results but also on Federal Reserve decisions, quarterly earnings, and even crypto price moves. This year alone, more than $200 million changed hands on Polymarket contracts linked to the Fed’s recent 25 bps rate cut, while $85 million traded on Kalshi around the same decision. Mainstream brokers like Coinbase and Robinhood are watching closely, with ambitions to capture some of the momentum. With U.S. sports betting already worth tens of billions annually, the overlap is too big to ignore. Against that backdrop, Kalshi has delivered one of its strongest months since the 2024 elections. The platform reports $1.3 billion in trading volume so far in September, accounting for 62% of global prediction market activity. Just a year ago, Kalshi’s share stood at 3%. CEO Tarek Mansour called the growth “remarkable,” noting that the exchange still serves only U.S. clients. Polymarket’s Pushback Its main rival, Polymarket, has logged about $773 million in trades this month. While that trails Kalshi for now, Polymarket has unique advantages: as a crypto-native platform, it has carved out strong global demand and is working toward a formal U.S. relaunch via its acquisition of derivatives exchange QCEX. The two platforms now stand as the clear leaders of the sector, though they embody different philosophies — one regulated from the ground up, the other built around decentralization. Investors Take Notice The boom hasn’t escaped venture capital. Reports suggest…
Share
BitcoinEthereumNews2025/09/19 21:34
Visa Expands USDC Stablecoin Settlement For US Banks

Visa Expands USDC Stablecoin Settlement For US Banks

The post Visa Expands USDC Stablecoin Settlement For US Banks appeared on BitcoinEthereumNews.com. Visa Expands USDC Stablecoin Settlement For US Banks
Share
BitcoinEthereumNews2025/12/17 15:23
Bitcoin Lightning Network Capacity Surges to Historic Peak as Exchange Adoption Accelerates

Bitcoin Lightning Network Capacity Surges to Historic Peak as Exchange Adoption Accelerates

The Bitcoin Lightning Network has reached an all-time high in total network capacity, marking a significant milestone for the layer-2 scaling solution designed to enable fast and inexpensive Bitcoin transactions. The surge comes as major cryptocurrency exchanges increasingly integrate Lightning functionality, bringing the technology to millions of users who previously relied solely on slower, more expensive on-chain transactions. This capacity expansion reflects growing confidence in Lightning's reliability and utility after years of development and real-world testing. What began as an experimental protocol discussed primarily among technical enthusiasts has matured into infrastructure that some of the industry's largest platforms now consider essential to their operations.
Share
MEXC NEWS2025/12/17 17:14